CEVR’s Tara Lavelle: Tufts-CEVR’s CEA Registry is a powerful, tool that can inform evidence-based health benefit design, new research proposals, and judgments on the value of health care interventions. More at cear.tuftsmedicalcenter.org

Conversations about drug pricing/value benefit from launch price transparency. New CEVR research finds that, from 2022-2024, pharma companies disclosed 1/3 of drug launch prices proactively and another 1/3 reactively, suggesting room for improvement. More at tinyurl.com/dsfjft4k

Do US health plans clearly explain how patients can start and stay on neuromuscular disease (NMD) therapies? New CEVR research suggests that they often do not. Read more about payer transparency/restrictiveness across several NMDs, including #DMD, #SMA, #ALS, and more. tinyurl.com/mr2cxc52

What is the outlook for US payer coverage of specialty drugs in 2026? CEVR’s James Chambers will share insights from our SPEC database during a “can’t miss” webinar next week. When: December 18, 12-12:30 pm ET Register at tinyurl.com/56959f62

The Centers for Medicare and Medicaid Services (#CMS) recently released the maximum fair prices (#MFP) for the 15 #IPAY 2027 drugs. How closely do they align with value-based prices? New CEVR research found wide variation, which sends muddled signals to drugmakers about value. tinyurl.com/3jsuybc7

Excited to announce 1st paper in new Health Affairs Scholar Series #HAS @Health_Affairs by @TuftsCEVR. For almost 20 years, CEVR has been leader on issues pertaining to value, cost-effectiveness, and risk tradeoffs in health care decisions. Watch for more! academic.oup.com/healthaffair...

Some drugmakers are rolling out “pharm-to-table” programs to sell drugs directly to patients at lower costs, but how much will these programs to improve access and price transparency? Read CEVR’s commentary on the promises and pitfalls of these programs. tinyurl.com/mrv8dczp

Did you publish a #CEA in 2025? Applications are now open for the 8th annual Tufts-CEVR CEA Paper of the Year Award. Est. application time: <5 mins Award: $500 Due: January 15th: forms.gle/hiPo3nYSE8rV... #HEOR #healthecon #HTA

Only 25% of cost-effectiveness analyses published from 2013-23 (n=7,800) omit societal costs (productivity, caregiving, travel, etc.), despite consensus guidelines recommending their inclusion. Read at tinyurl.com/3htu3zn9

The Inflation Reduction Act (#IRA) allows #Medicare to defer negotiation for drugs with expected biosimilar competition within 2 years of selection, but this provision may unintentionally reduce long-term savings according to new research from CEVR. More at: tinyurl.com/nptjvxzb

Rapid genome sequencing performed early in a hospitalization can save ~$160k for critically ill infants with suspected genetic conditions- but most US insurers do not cover it. Read more about this new Tufts Medical Center research: tinyurl.com/yc7mmxs7

Come see CEVR's faculty at ISPOR Europe 2025 in Glasgow, Scotland. Details of our speaking engagements can be found at tinyurl.com/4em5ak2t #ISPOREurope

Join CEVR on Nov. 5 from 2:30-3:30 pm ET for a health policy seminar from Boshen Jiao, PhD, MPH. Dr. Jiao will discuss the inclusion of productivity, informal caregiving time, and future unrelated medical costs in economic evaluations. More at: tinyurl.com/4ru3pmd8

CEAs of SMA treatments frequently omit the effects of bereavement on caregivers, potentially undervaluing these interventions. Our new survey of bereaved parents better quantifies their experience of grief to inform future CEAs. Read more at: tinyurl.com/2mcs6taa

The death of a child with SMA is a life-changing experience for parents, impacting their outlook on life, health, relationships, employment. New qualitative research explores the impacts of grief and strategies that help bereaved parents manage the loss of their child. Read: tinyurl.com/mw2s2ezw

Going to AMCP 2025? Come see presentations by @mollytoba.bsky.social, Daniel Enright, and Angela Lin of CEVR's SPEC Team! #AMCPNexus

US commercial payers vary in how they cover cell and gene therapies, according to a new study of 541 coverage policies by Tufts-CEVR’s SPEC team. 52% of policies had restrictions beyond FDA label, often limiting access to patient subgroups or requiring step therapy. Read at: tinyurl.com/5dwhv726

CEAs often undervalue vaccines by excluding family spillover effects. New research from CEVR and Merck explores the impact of omissions. Half of studied CEAs omitted spillover effects. Including them improved cost-eff. by avg. of ~20%; 10% of results became cost-saving. Read: tinyurl.com/y8p6jtwm

Older adults with dementia face substantial OOP costs. New CEVR research explores financial risks to patients/families: 21% of individuals w/ severe dementia face catastrophic costs; 12% fall below poverty threshold due to costs. Read at: tinyurl.com/3pfbt7fp @pattysynnott.bsky.social

Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss new research to standardize definitions and outcomes reporting for patient-facing digital health interventions (PICOTS-ComTeC and CHEERS-DHI) More at: tinyurl.com/ywn7abjp

Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss his work to define patient-facing digital health interventions and standardize reporting practices (PICOTS-ComTeC and CHEERS-DHI) More at: tinyurl.com/ywn7abjp

How can we make #valueassessment more patient-centric? New consensus recs from CEVR’s Tara Lavelle & colleagues include: • Engage patients throughout • Count all costs to patients & caregivers • Share results in plain language Read all 28 recommendations here: tinyurl.com/m9wxf6wj

New in Health Affairs: CMS should adopt a formal #HTA approach for #IRA drug price negotiations. Benefits: transparency, broader evidence, more patients/stakeholder input, more acceptance of negotiations, etc. More from @dano-hta.bsky.social et al: tinyurl.com/2s36yjta @commonwealthfund.org

What explains the wide range of specialty drug rebates? New research from @mollytoba.bsky.social et al finds cancer/orphan drugs have the lowest rebates, and biosimilars/originators the highest. Read more in Health Affairs Scholar at: tinyurl.com/y4rc468d @argenx.com #PBM #Rebates #DrugPrices

CEVR is thrilled to welcome David Strutton, PhD, as a Senior Fellow! Dr. Strutton brings 30+ years of global leadership in health policy, biopharma, and HTA. His expertise in real-world evidence and access strategy will be a tremendous asset. Read more at: tinyurl.com/3bz9te3p

Meet Hao-Hsin (Taylor) Huang, MS, today’s featured #CEARegistry Summer Fellow. Taylor is pursuing her PhD in Pharmacy Systems, Outcomes, and Policy at the University of Illinois, Chicago. Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!

Great application of our CEA Registry at the #Vanderbilt Center for Health Economic Modeling: 11 international fellows from #LMICs used the Registry to conduct CEAs of public health interventions. Read more at: tinyurl.com/88varaue @peterneumann11.bsky.social #ISPOR

New in JCER: CEVR’s Meng Li and @peterneumann11.bsky.social call for more value assessment of health services/procedures. These interventions are ~70% of health care spending but are often implemented without robust evidence and, unlike drugs, can cost more over time. Read: tinyurl.com/ycxrppby

CEVR Summer Fellow Spotlight: we’re thrilled to have Rosemond Amamoo, MD, MPH as a #CEARegistry Summer Fellow! Rosemond is pursuing her PhD in Health and Pharmaceutical Outcomes at @uarizona.bsky.social. Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!

Two weeks left to apply: Earn your #HEOR Certificate online from @tufts.edu with globally-recognized faculty like @peterneumann11.bsky.social, @dano-hta.bsky.social, James Chambers, and more from CEVR. Apply today! Deadline is Aug. 1. tinyurl.com/pr6drkhf #RWE #pharma

Today’s #CEARegistry Summer Fellow is Pooja Gokhale, PharmD. Pooja is pursuing her PhD in Pharmaceutical Health Services, Outcomes, and Policy at @universityofga.bsky.social. Our thanks to @moorefound.bsky.social for funding the CEA Registry Fellowship program!‬‬

Larry Mose, MSc is today’s #CEARegistry Summer fellow. Larry earned his MSc from @york.ac.uk and hopes to work in the field of #HEOR. Our thanks to the @moorefound.bsky.social ‬for funding the CEA Registry Fellowship program!‬‬

1/ How closely do health plans’ drug #utilizationmanagement (UM) policies align with #clinicalguidelines? CEVR and NPC examined policies for 389 drug-indication pairs from 18 commercial insurers. Here’s a thread on what we found:

Strategic evidence planning in the IRA: Insights from Year 1 drug price negotiations | becarispublishing.com/digital-cont...

Traditional #valueassessment lacks methods to evaluate #oncology combination txs, posing challenges for drugmakers, HTA bodies, and payers. In a new commentary in Frontiers in Pharmacology, CEVR’s Dan Ollendorf et al explore available frameworks and chart a path forward: tinyurl.com/kh84ueb4

Meet Fengdi Zhang, MPH, today's featured #CEARegistry Summer Fellow. Fengdi is pursuing her PhD in Pharmaceutical Health Services Research at @univofmaryland.bsky.social Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!

There are new drugs for #Alzheimer’s but utility data for AD patients and caregivers are limited/outdated. A new survey from CEVR’s Lin et al and UsAgainstAlzheimer's provides fresh data, stratifies utilities by care setting, etc. Read in J Alzheimer’s Dis: tinyurl.com/mu5rt9yd #HEOR

Meet Hanxuan (Astrid) Yu, MEd, today’s #CEARegistry summer fellow. Astrid is working toward her PhD at @hsph.harvard.edu Our thanks to @moorefound.bsky.social for funding the CEA Registry Fellowship program!‬

CEVR is thrilled to introduce the 2025 cohort of the Tufts-CEVR CEA Registry Summer Fellowship Program, which is supported by the @moorefound.bsky.social. Stay tuned over the next two months for featured posts about each fellow! More details at: cevr.tuftsmedicalcenter.org/news/2025-ce...

Join our team! CEVR is #hiring a research project coordinator: cevr.tuftsmedicalcenter.org/news/researc...

Join CEVR on June 17 from 2-3 ET for a health policy seminar from Nathaniel Hendrix, PhD, PharmD. Dr. Hendrix will discuss trends in and effects of pharmaceutical industry payments to primary care physicians. More details at: tinyurl.com/3e2nesrc

New in Value in Health: three former CEA Registry Summer Fellows (Xujun Gu, Hanwen Zhang, and Divya Patil) and U of Maryland's Julia Slejko used the CEA Registry to explore the utility of AI-assisted data extraction. Read at tinyurl.com/37mh5n6m

In recognition of her expertise in health economics, CEVR Senior Fellow Melanie Whittington, PhD, has been appointed to the Congressional Budget Office (#CBO) 2025 Panel of Health Advisors. Congratulations Melanie! Read the CBO announcement at tinyurl.com/ms7j82c6

This is great news for ISPOR student and LMIC members. The CEVR registry is an invaluable tool - both for researchers trying to find high quality cost-effectiveness analyses within a specific clinical area and for those looking a bigger trends in the economic evaluation literature. #HEOR #EconSky

ISPOR and CEVR are partnering to offer free premium access to the CEA Registry for students + academic/government researchers in LMICs. Unlock data from 14,000+ cost-effectiveness studies, advanced tools, and more. More at: tinyurl.com/5y3vpsz3 #HEOR #GlobalHealth #ISPOR

With @tuftscevr.bsky.social colleagues #ISPORAnnual in Montreal.

Gearing up for a busy #ISPORAnnual for the @tuftscevr.bsky.social SPEC team! Come say hello, learn about our research and the SPEC database. #heor #marketaccess #healthpolicy

Join CEVR on May 6 from 4-5 ET for a health policy seminar from Dr. Noemi Kreif. Dr. Kreif will discuss how machine learning can help evaluate treatment effectiveness and personalize treatment recommendations. More details at: tinyurl.com/3z4cwyn8 #machinelearning

Come see CEVR's faculty and researchers share their work and insights at #ISPOR2025 in Montreal! A list of our panels, workshops, poster presentations, and other activities can be found at tinyurl.com/mwy8yv3a #ISPOR #HEOR #HealthPolicy

Join CEVR’s James Chambers at the World Orphan Drug Conference USA tomorrow, April 22, in Boston. James will present his research on the health benefits, costs, and cost-effectiveness of ultraorphan drugs. More at: tinyurl.com/yer2ssfc #WorldOrphanUSA #HEOR